SynthesisWorld journal of gastroenterology2013
Endoscopic and surgical resection of T1a/T1b esophageal neoplasms: a systematic review.
Synthesis in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06979986 (Systematically Mediastinal Lymph Node Dissection), which is not on this map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Systematically Mediastinal Lymph Node Dissection (SLND) Versus Non-Dissection Following Endoscopic Submucosal Dissection (ESD) for T1a Stage Esophageal Squamous Cell Carcinoma
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Endoscopic resection versus esophagectomy for T1bN0M0 esophageal cancer: a systematic review and meta-analysis.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2026Pooled it
- Efficacy and complication of endoscopic submucosal dissection for superficial esophageal carcinoma: a systematic review and meta-analysis.Journal of cardiothoracic surgery · 2014Pooled it
- Durability of radiofrequency ablation for treatment of esophageal squamous cell neoplasia: 5-year follow-up of a treated cohort in China.Gastrointestinal endoscopy · 2019Trial
- Trial
- Mapping Two Decades of Research on Endoscopic Submucosal Dissection in Esophageal Cancer: A Bibliometric and Visual Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Risk factors for non-curative resection after endoscopic submucosal dissection for early esophageal lesions and analysis of secondary treatment efficacy.Surgical endoscopy · 2026Article
- Endoscopic Submucosal Dissection Followed by Chemoradiotherapy Versus Radiotherapy in Patients with Stage T1bN0M0 Esophageal Cancer.Journal of gastrointestinal cancer · 2025Article
- From endoscopy to surgery: a translational perspective on early esophageal cancer management.Frontiers in medicine · 2025Article
- Long-Term Follow-Up After Non-Curative Endoscopic Submucosal Dissection for Early Gastrointestinal Cancer-A Retrospective Multicenter Analysis.Journal of clinical medicine · 2024Article
- Successful endoscopic treatment of superficial esophageal cancer in a patient with esophageal variceal bleeding: A case report.World journal of clinical cases · 2024Article
- Management of early oesophageal cancer: An overview.World journal of gastrointestinal surgery · 2024Article
- Using Pathomics-Based Model for Predicting Positive Surgical Margins in Patients with Esophageal Squamous Cell Carcinoma: A Comparative Study of Decision Tree and Nomogram.International journal of general medicine · 2024Article
- Endoscopic Submucosal Dissection in the Upper Gastrointestinal Tract and the Need for Rescue Surgery-A Multicenter Analysis.Journal of clinical medicine · 2023Article
- Ten-year follow-up of endoscopic mucosal resection versus esophagectomy for esophageal intramucosal adenocarcinoma in the setting of Barrett's esophagus: a Canadian experience.Surgical endoscopy · 2023Article
- Management of esophageal neoplasms by endoscopic submucosal dissection: experience over 100 consecutive procedures.Clinical endoscopy · 2023Article
- Miniature side-view dual axes confocal endomicroscope for repetitive in vivo imaging.Biomedical optics express · 2023Article
- Associated risk factor analysis and the prognostic impact of positive resection margins after endoscopic resection in early esophageal squamous cell carcinoma.Experimental and therapeutic medicine · 2022Article
- Endoscopic resection with adjuvant treatment versus esophagectomy for early-stage esophageal cancer.Surgical endoscopy · 2022Article
- Article
- Modeling the impact of delaying surgery for early esophageal cancer in the era of COVID-19.Surgical endoscopy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate potential therapeutic recommendations for endoscopic and surgical resection of T1a/T1b esophageal neoplasms.
methodsA thorough search of electronic databases MEDLINE, Embase, Pubmed and Cochrane Library, from 1997 up to January 2011 was performed. An analysis was carried out, pooling the effects of outcomes of 4241 patients enrolled in 80 retrospective studies. For comparisons across studies, each reporting on only one endoscopic method, we used a random effects meta-regression of the log-odds of the outcome of treatment in each study. "Neural networks" as a data mining technique was employed in order to establish a prediction model of lymph node status in superficial submucosal esophageal carcinoma. Another data mining technique, the "feature selection and root cause analysis", was used to identify the most important predictors of local recurrence and metachronous cancer development in endoscopically resected patients, and lymph node positivity in squamous carcinoma (SCC) and adenocarcinoma (ADC) separately in surgically resected patients.
resultsEndoscopically resected patients: Low grade dysplasia was observed in 4% of patients, high grade dysplasia in 14.6%, carcinoma in situ in 19%, mucosal cancer in 54%, and submucosal cancer in 16% of patients. There were no significant differences between endoscopic mucosal resection and endoscopic submucosal dissection (ESD) for the following parameters: complications, patients submitted to surgery, positive margins, lymph node positivity, local recurrence and metachronous cancer. With regard to piecemeal resection, ESD performed better since the number of cases was significantly less [coefficient: -7.709438, 95%CI: (-11.03803, -4.380844), P < 0.001]; hence local recurrence rates were significantly lower [coefficient: -4.033528, 95%CI: (-6.151498, -1.915559), P < 0.01]. A higher rate of esophageal stenosis was observed following ESD [coefficient: 7.322266, 95%CI: (3.810146, 10.83439), P < 0.001]. A significantly greater number of SCC patients were submitted to surgery (log-odds, ADC: -2.1206 ± 0.6249 vs SCC: 4.1356 ± 0.4038, P < 0.05). The odds for re-classification of tumor stage after endoscopic resection were 53% and 39% for ADC and SCC, respectively. Local tumor recurrence was best predicted by grade 3 differentiation and piecemeal resection, metachronous cancer development by the carcinoma in situ component, and lymph node positivity by lymphovascular invasion. With regard to surgically resected patients: Significant differences in patients with positive lymph nodes were observed between ADC and SCC [coefficient: 1.889569, 95%CI: (0.3945146, 3.384624), P < 0.01). In contrast, lymphovascular and microvascular invasion and grade 3 patients between histologic types were comparable, the respective rank order of the predictors of lymph node positivity was: Grade 3, lymphovascular invasion (L+), microvascular invasion (V+), submucosal (Sm) 3 invasion, Sm2 invasion and Sm1 invasion. Histologic type (ADC/SCC) was not included in the model. The best predictors for SCC lymph node positivity were Sm3 invasion and (V+). For ADC, the most important predictor was (L+).
conclusionLocal tumor recurrence is predicted by grade 3, metachronous cancer by the carcinoma in-situ component, and lymph node positivity by L+. T1b cancer should be treated with surgical resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.